For research use only. Not for therapeutic Use.
CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].
CDDD11-8 (0-3 μM, 24 h) suppresses the expressions of c-MYC, MCL-1, and XIAP in MV4-11 and MOLM-13 cells[1].
CDDD11-8 dose-dependently inhibits proliferation (IC50 range: 281-734 nM), induces cell cycle arrest, and increases apoptosis of cell lines[2].
CDDD11-8 (0-125 mg/kg, PO, daily) induces tumor regression[1].
| Catalog Number | I040151 |
| CAS Number | 2241659-94-7 |
| Synonyms | 4-N-[5-methyl-4-(6-phenylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]cyclohexane-1,4-diamine |
| Molecular Formula | C24H26N6 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H26N6/c1-16-13-27-24(28-20-10-8-19(25)9-11-20)29-23(16)21-14-26-22-12-7-18(15-30(21)22)17-5-3-2-4-6-17/h2-7,12-15,19-20H,8-11,25H2,1H3,(H,27,28,29) |
| InChIKey | OVOYRPVIZNJKHS-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(N=C1C2=CN=C3N2C=C(C=C3)C4=CC=CC=C4)NC5CCC(CC5)N |
| Reference | [1]. Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel). 2022 Feb 22;14(5):1113. [2]. Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24. |
